XML 102 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges
6 Months Ended
Jun. 30, 2013
Restructuring Charges
15.          Restructuring Charges
 
In December 2012 the Company announced the closure of its tissue engineering facility in Abano Terme, Italy due to the inability to meet strict regulatory standards, effective January 1, 2013, established by the EMA for Advanced Therapy Medicinal Products. The restructuring plan involved a workforce reduction as well as associated asset abandonments. The Company recorded restructuring and impairment charges in the fourth quarter of 2012 of approximately $2.5 million. Of the total restructuring and impairment charges related to the tissue engineering operation, approximately $1.2 million related to the non-cash termination and related impairment of an IPR&D project, $0.3 million related to the disposal of property and equipment, and $0.1 million related to the disposal of inventory. The remaining $0.9 million relates to cash payments that are anticipated to occur in 2013, primarily for employee termination costs.

We made substantial progress in the six months ending June 30, 2013 in completing the planned restructuring. We sold certain previously impaired and written-off equipment, resulting in restructuring credit of $111,178 and $246,785 in the three and six months ended June 30, 2013, respectively. The carrying value of the restructuring accrual approximated fair value at June 30, 2013.

The following table summarizes restructuring accrual activity for the six months ended June 30, 2013:
 
   
 Restructuring Accrual
   
Employee
Severance and
Related Benefits
 
Activity
Termination and
Facility Closure
Costs
 
Total
December 31, 2012
  $ 801,453     $ 132,279     $ 933,732  
Charges to Operations
    -       -       -  
Cash Proceeds, Disbursements
    (613,870 )     (45,240 )     (659,110 )
Write Offs and Abandonments
    -       -       -  
Foreign Exchange Impact
    8,422       19       8,441  
June 30, 2013
  $ 196,005     $ 87,058     $ 283,063